InvisiShield Technologies, Ltd.
Pre-clinical-stage biotechnology company developing intranasal preventive therapies to neutralize airborne respiratory viruses at the nasal mucosa. The organization develops a platform that combines a pathogen-binding component, a virus-killing mechanism that activates complement, and a formulation approach to increase nasal retention. Lead development is an intranasal topical preventive intended to provide immediate, short-term protection against SARS-CoV-2, with the platform being applied to influenza and RSV. Headquartered in Emeryville, California.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections
US-12459988-B2
View DetailsCompositions for preventing or treating viral and other microbial infections
US-11440952-B2
View Details
Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections
US-12459988-B2
View DetailsCompositions for preventing or treating viral and other microbial infections
US-11440952-B2
View DetailsProducts
Intranasal COVID-19 preventive spray (lead candidate)
Pre-clinical intranasal topical formulation designed to bind and neutralize SARS-CoV-2 in the nasal cavity, incorporating enhanced mucosal retention and a complement-activating killing mechanism. Demonstrated prevention of infection in cell-based assays and at least 10 hours of protection in mouse challenge studies at the lowest tested dose.
IS101
An intranasal COVID-19 preventive spray that provides daily protection on the nasal cavity surface, the principal portal of viral entry.
InvisiShield COVID-19 intranasal preventive (IS101)
A topical daily use nasal spray designed to provide immediate protection against SARS-CoV-2 infection by binding the virus and using proprietary nasal retention technology to capture and kill all major current and potential future variants in the nasal cavity.
InvisiShield's COVID-19 intranasal preventive spray
An intranasal spray designed to prevent SARS-CoV-2 infection by providing protection at the nasal mucosa, the primary entry point for the virus.
Intranasal COVID-19 preventive spray (lead candidate)
Pre-clinical intranasal topical formulation designed to bind and neutralize SARS-CoV-2 in the nasal cavity, incorporating enhanced mucosal retention and a complement-activating killing mechanism. Demonstrated prevention of infection in cell-based assays and at least 10 hours of protection in mouse challenge studies at the lowest tested dose.
IS101
An intranasal COVID-19 preventive spray that provides daily protection on the nasal cavity surface, the principal portal of viral entry.
InvisiShield COVID-19 intranasal preventive (IS101)
A topical daily use nasal spray designed to provide immediate protection against SARS-CoV-2 infection by binding the virus and using proprietary nasal retention technology to capture and kill all major current and potential future variants in the nasal cavity.
InvisiShield's COVID-19 intranasal preventive spray
An intranasal spray designed to prevent SARS-CoV-2 infection by providing protection at the nasal mucosa, the primary entry point for the virus.
Expertise Areas
- Intranasal drug delivery and mucosal formulations
- Preclinical virology and immunology research
- In vivo infectious disease models (mouse challenge studies)
- In vitro pseudotyped-virus neutralization assays
Key Technologies
- Intranasal drug delivery
- Mucosal adhesion / nasal retention formulations
- Pathogen-binding biologic agents
- Complement activation–based viral neutralization
News & Updates
Announcement of a scientific advisory board composed of experts in virology and immunology to advise preclinical development.
Collaboration to accelerate development of intranasal preventatives against SARS-CoV-2, influenza, and RSV including partnered preclinical studies and access to BSL-3 testing facilities.
Announcement of appointment of a senior virology researcher to lead scientific strategy and accelerate clinical development pathways.
Announcement of a scientific advisory board composed of experts in virology and immunology to advise preclinical development.
Collaboration to accelerate development of intranasal preventatives against SARS-CoV-2, influenza, and RSV including partnered preclinical studies and access to BSL-3 testing facilities.
Announcement of appointment of a senior virology researcher to lead scientific strategy and accelerate clinical development pathways.